A CDC official said today that States have begun preparing to distribute a COVID-19 vaccine if one is approved. "Every jurisdiction is heavily involved right now in their plan development," CDC official Janell Routh, MD, told the Advisory Committee on Immunization Practices during its September 22 meeting. "It was really impressive to me that even though the playbook only went out last week, states and jurisdictions have been thinking about this for quite some time."
President Emmanuel Macron said on Tuesday that France must do everything possible to avoid locking up elderly people in nursing homes to protect them from a resurgence in coronavirus infections nationwide. Almost 31,340 people in France have died from COVID-19, the health ministry said on Monday, and the cumulative number of cases stood at more than 458,000.
A study was published online September 14 states shows light therapy statistically significantly altered multiple diffusion tensor parameters in the late subacute stage. The trial provides evidence that light therapy engages the neural substrates that affect the pathophysiologic factors associated with moderate traumatic brain injury. Animal studies have shown that functional recovery from Traumatic Brain Injury is improved with low-level light therapy. In one such investigation, mice that were treated with low-level light therapy for 4 hours after Traumatic Brain Injury had a better functional outcome than mice that were exposed to a sham treatment.
Alexis Cournoyer et.al. conducted a study to synthesize the evidence regarding the infection risk associated with different modalities of oxygen therapy used in treating patients with severe acute respiratory infection. The researchers concluded that the lowest flow of oxygen should be used to maintain an adequate oxygen saturation for patients with severe acute respiratory infection, and manipulation of oxygen delivery equipment should be minimized.
Fabienne Moret et.al. presented a case of a 52-year-old patient presented to the emergency department due to burning pain on his proximal right thigh and scrotum. Clinical examination showed an 8 × 5 cm measuring burning wound resembling lesion. During further history the patient mentioned that the day before presentation a “poppers” phial unintentionally opened in his pocket and the fluid leaked. The present case shows severe skin defects after skin-contact with alkyl nitrates in a “poppers” user.
In this study, the effects of metformin and insulin treatment on maternal serum lipids were compared in patients with gestational diabetes (GDM), and to examine the relationships between individual lipids and birth weight (BW). Researchers designed a secondary analysis of a randomized trial to compare metformin (n=110) and insulin (n=107) treatment of GDM. They assessed fasting serum lipidome at baseline (the time of diagnosis, mean 30 gestational weeks, gw) and at 36 gw applying nuclear magnetic resonance spectroscopy. The data revealed that metformin treatment of GDM led to higher maternal serum concentrations of triglyceride-rich lipoproteins in comparison with insulin. In VLDL, particularly triglycerides and cholesterol were positively correlated with BW. The evidence suggested that women with high VLDL cholesterol or high apoB/apoA-1 may benefit from insulin treatment over metformin with respect to offspring BW.
Researchers conducted this multicentre observational analysis to assess the safety profile in terms of changes in renal function after co‐treatment with sacubitril/valsartan and empagliflozin in patients with type 2 diabetes (T2D) and heart failure with reduced ejection fraction (HFrEF). The sample consisted of 108 patients with T2D and HFrEF treated with both agents: baseline sacubitril/valsartan (Group A; n = 43), baseline empagliflozin (Group B; n = 42), or both agents initiated simultaneously (Group C; n = 23). Sacubitril/valsartan and empagliflozin co-administration tend to be safe in terms of renal function in patients with HFrEF and concomitant T2D.
In view of a wide variation in survival of patients with stage III colon cancer according to T-N sub-stages, it appears that determination of the benefit of each therapeutic option in each T-N subgroup may yield more precise information and will assist doctors and patients in the complex shared decision-making process surrounding adjuvant therapy. From the IDEA trial, they retrieved the outcomes data of 12,834 patients with stage III colon cancer and categorized the patients in 16 sub-stages, based on T-N categories. The subgroups were noted to vary largely in 5-year DFS rate, ranging from 89% (T1N1a) to 31% (T4N2b) in the overall population. Wide variation was noted in the contribution of each therapeutic option across sub-stages. The resulting overlay bar graph indicated the absolute advantage of each treatment option. The model indicated a projected 5-year DFS of 79.6% for patients with T1N1a cancers in correlation with receiving surgery alone. A 5.6% absolute DFS gain was recorded in correlation with providing adjuvant fluoropyrimidine alone; an additional 2.3% and 0.8% gain is noted with oxaliplatin for 3 and 6 months, respectively. Patients with T4N2b cancers displayed a 13.9% 5-year DFS with surgery alone, and an 11.2%, 6.4%, 2.5% rise with the aforementioned adjuvant options, respectively.
Shu-Ting Zhu et al prospectively assessed the utility of point-of-care lung ultrasound for the clinical classification of coronavirus disease (COVID-19). Bedside lung ultrasonography (LUS) examinations were performed three times on 27 adult patients with COVID-19 within the first 2 weeks of admission to the isolation ward. Eighty-one exams were divided into three groups (ie, moderate group, severe group, and critically ill group). They determined lung scores as the sum of points. The three groups differed dramatically in LUS, and positive correlation was noted between LUS scores and clinical severity. Moreover, moderate, severe, and critically ill patients more frequently had low (≤ 9), medium (9-15), and high scores (≥ 15), respectively. This work yields stratification criteria of LUS scores to allow quantitative evaluation of COVID-19 patients.
A recent study suggests that patients aged 75 and older who undergo cancer surgery have lower 90-day postoperative mortality when they receive geriatric co-management than when they don't. Researchers examined data on 1,892 patients 75 and older who had elective surgery with at least a one-day hospital stay at Memorial Sloan Kettering Cancer Center in New York City, including 1,020 patients who received geriatric co-management.